Related Experiment Videos
[Inflammatory response, cholesterol metabolism, and arteriosclerosis]
A Salazar Soler1, X Pinto Sala, J Maña Rey
1Servicio de Medicina Interna, Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona.
Anales De Medicina Interna (Madrid, Spain : 1984)
|April 27, 2001
Summary
Systemic granulomatous diseases like sarcoidosis impact cholesterol metabolism. Serum amyloid A, an acute phase reactant, may promote atherosclerosis by altering high-density lipoproteins and affecting the endothelium.
Area of Science:
- Biochemistry
- Immunology
- Cardiovascular Science
Context:
- Inflammatory disorders, specifically systemic granulomatous diseases like sarcoidosis, are increasingly recognized for their complex interplay with metabolic processes.
- Cholesterol metabolism plays a critical role in cardiovascular health, and its dysregulation is a hallmark of atherosclerosis.
Purpose:
- To review the relationship between inflammatory disorders and cholesterol metabolism.
- To elucidate the role of Serum Amyloid A (SAA) in the context of atherosclerosis development.
- To explore the pathophysiological links between SAA concentrations and atherosclerotic processes.
Summary:
- Serum amyloid A (SAA), an acute phase reactant, binds to high-density lipoproteins (HDL) during inflammation.
- SAA can displace apolipoprotein A-I (apo A-I), increasing HDL catabolism, or inhibit lecithin-cholesterol acyltransferase (LCAT), reducing esterified cholesterol levels.
- These lipoprotein alterations, coupled with SAA's direct effects on atherosclerotic plaque endothelium, suggest a mechanism linking inflammation to atherosclerosis.
Impact:
- Provides a comprehensive overview of the molecular mechanisms connecting inflammation and atherosclerosis.
- Highlights the potential of SAA as a biomarker and therapeutic target in cardiovascular disease.
- Enhances understanding of sarcoidosis and other granulomatous diseases' impact on lipid metabolism and cardiovascular risk.